18 Prostate Cancer Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Prostate Cancer Studies in Phoenix

NCT06925737Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-...

Phoenix, AZPHASE31,440 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03678025Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer...

Phoenix, AZPHASE31,273 participantsSWOG Cancer Research Network

View Study Details

NCT07028853Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who ar...

Phoenix, AZPHASE31,000 participantsPfizer

View Study Details

NCT06629779Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abirat...

Phoenix, AZPHASE3900 participantsPfizer

View Study Details

NCT06592924Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like ...

Phoenix, AZPHASE3830 participantsCanadian Cancer Trials Group

View Study Details

NCT04423211Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to st...

Phoenix, AZPHASE3804 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT06952803Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment ...

Phoenix, AZPHASE3700 participantsAstraZeneca

View Study Details

NCT07611110Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in ...

Phoenix, AZPHASE3670 participantsAstraZeneca

View Study Details

NCT06378866Recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT...

Phoenix, AZPHASE2532 participantsMayo Clinic

View Study Details

NCT06056830Recruiting

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases....

Phoenix, AZPHASE3383 participantsClarity Pharmaceuticals Ltd

View Study Details

NCT03972657Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with ce...

Phoenix, AZPHASE1345 participantsRegeneron Pharmaceuticals

View Study Details

NCT05519449Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults...

Phoenix, AZPHASE1272 participantsJanux Therapeutics

View Study Details

NCT06873581Recruiting

Pivotal Study of Voro Urologic Scaffold

The objective of this study is to compare safety and effectiveness of the Voro Urologic Scaffold in adult men undergoing robotic assisted radical prostatectomy as compared to control arm. The study i...

Phoenix, AZPHASE3266 participantsLevee Medical, Inc.

View Study Details

NCT06533644Recruiting

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b stud...

Phoenix, AZPHASE291 participantsSyncromune, Inc.

View Study Details

NCT04550845Recruiting

Understanding of Genetics by Men at Risk for Prostate Cancer

With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understand...

Phoenix, AZNA90 participantsMayo Clinic

View Study Details

NCT06990880Recruiting

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose e...

Phoenix, AZPHASE185 participantsGlaxoSmithKline

View Study Details

NCT05488548Recruiting

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies...

Phoenix, AZPHASE175 participantsEpigenetix, Inc.

View Study Details

NCT05806515Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medi...

Phoenix, AZPHASE244 participantsSWOG Cancer Research Network

View Study Details

About Prostate Cancer Clinical Trials in Phoenix

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 18 prostate cancer clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 9,800 participants. Research is being sponsored by Merck Sharp & Dohme LLC, SWOG Cancer Research Network, Pfizer and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Phoenix — FAQ

Are there prostate cancer clinical trials in Phoenix?

Yes, there are 18 prostate cancer clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 18 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated July 18, 2026 from ClinicalTrials.gov